Merck Opens M Lab(TM) Collaboration Center in Sao Paulo, Brazil

Food and Healthcare Press Releases Friday October 5, 2018 09:07
SAO PAULO--5 Oct--PRNewswire/InfoQuest
  • New collaboration center to provide support from pre-clinical through full-scale production in a non-GMP environment
  • Hands-on customer access to Merck's product portfolio, technical expertise

Merck, the vibrant science and technology company, today officially opened a state-of-the-art M Lab(TM) Collaboration Center in Brazil, serving the Latin America region. The center will provide Life Science customers with a shared, exploratory environment where they can closely collaborate with Merck scientists and engineers to solve their toughest challenges and accelerate development and production of new therapies.

"With a rapidly growing biopharmaceutical industry in Brazil and Latin America, and demand for novel and cost-effective therapies worldwide, there is a need for full end-to-end process development support," said Udit Batra, member of the Merck Executive Board and CEO, Life Science. "At our M Lab(TM) Collaboration Center, customers will benefit from Merck's deep technical expertise to develop processes for manufacturing drugs faster, safer and more effectively than in the past."

The 1,000-square meter lab facility includes non-GMP pilot and bench scale labs for customers to engage in process development support, troubleshooting, demonstrations and hands-on training. It is one of nine such centers around the world, each of which allows pharmaceutical manufacturers to explore new ways to increase productivity, improve processes and mitigate risks. Each year, more than 1,500 customers visit Merck's M Lab(TM) Collaboration Centers, where they work alongside Merck's team of experts and get access to sizing and simulation tools and methodologies as well as analytical and modeling support. Formal bioprocessing courses are also available, including traditional classroom-style training and interactive, hands-on sessions. Other M Lab(TM) Collaboration Center locations include China, Singapore, Japan, South Korea, India, France and the United States.

Merck opened its ?rst customer-facing laboratory in 1995 in Massachusetts, USA. The global network has steadily grown over the years, not only to meet the training and process development needs of customers in local regions, but also to allow and ensure successful technology transfer between countries for global customers. In 2015, Merck began reimagining these labs as the M Lab(TM) Collaboration Centers with a focus on customers.

Follow Merck on Twitter @Merckgroup, on Facebook @merckgroup and on LinkedIn.

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 53,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck generated sales of EUR15.3 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the "Merck" name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Photo - https://mma.prnewswire.com/media/752710/MilliporeSigma_M_Lab_Brazil.jpg

Latest Press Release

Kemin Launches New Vision and Logo for the Future

Global ingredient manufacturer sets sights on sustainably transforming 80 percent of the world by 2042 Today Kemin Industries, a global ingredient manufacturer, unveiled its new global vision and logo to align the company strategically for 2042 and...

Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial

Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with placebo, both in addition to standard of care. The...

Zeus Expands Portfolio with New Polyimide Family of Products

Products Include PI Tubing, PI Coated Wire, PI Glide(TM) Tubing, and PI Glide(TM) Coated Wire Zeus Industrial Products, Inc. (Zeus), a leading polymer solutions provider and material science innovator, has announced the introduction of a new polyimide...

SCG partners up with Frances Institut Pasteur to combat dengue with innovations to reduce mosquito breeding

Dr. Suracha Udomsak, Chief Technology Officer, on behalf of Chemicals Business, SCG, and Dr. Anavaj Sakuntabhai, Coordinator of the Defeat Dengue Program, Head of Structure, Functional Genetics of Infectious Diseases, representing Institut Pasteur,...

เอสซีจี จับมือ สถาบันปาสเตอร์ ฝรั่งเศส หยุดการระบาดของโรคไข้เลือดออกด้วยการพัฒนานวัตกรรมลดการแพร่พันธุ์ยุงลาย

ธุรกิจเคมิคอลส์ เอสซีจี โดย ดร.สุรชา อุดมศักดิ์ Chief Technology Officer และ สถาบันปาสเตอร์ ประเทศฝรั่งเศส (Institut Pasteur) โดย ดร. อนวัช ศกุนตาภัย Coordinator of the Defeat Dengue Program, Head of Structure, Functional Genetics of Infectious Diseases,...

Related Topics